Clinical Trials Sponsored by Yabao Pharmaceutical Group

Total 688 results

Yabao Pharmaceutical Group

Not yet recruiting

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects

Coronavirus Disease 2019
Yabao Pharmaceutical Group

Completed

Bioequivalence Study of Sorafenib Tablet and Nexavar

Fasting

Canada
Yabao Pharmaceutical Group

Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Hyperglycaemia (Diabetic)

China
Yabao Pharmaceutical Group

Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Healthy Volunteers | Hyperglycaemia (Diabetic)

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Recruiting

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Food-drug Interaction Study of SY-004 in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Tasly Pharmaceuticals, Inc.
Tasly Pharmaceutical Group Co., Ltd

No longer available

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Covid19

United States
Sinotau Pharmaceutical Group

Recruiting

A Study to Evaluate XTR006 in Chinese Volunteers

Alzheimer Disease

China
Xgene Pharmaceutical Group

Recruiting

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Acute Pain

United States
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
Sinotau Pharmaceutical Group

Completed

XTR003 PET Radiotracer for the Detection of Viable Myocardium

Ischemic Heart Disease (IHD)

China
Sinotau Pharmaceutical Group

Not yet recruiting

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Prostate Cancer

China
Sinotau Pharmaceutical Group

Completed

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

China
Sinotau Pharmaceutical Group

Completed

A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers

Coronary Artery Disease (CAD)

China
Sinotau Pharmaceutical Group

Recruiting

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

Alzheimer Disease

China
Sinotau Pharmaceutical Group

Not yet recruiting

Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors

Solid Tumor
Sinotau Pharmaceutical Group

Completed

Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

Coronary Artery Disease (CAD)

China
Sinotau Pharmaceutical Group

Completed

A Study of XTR004 Radiotracer in Healthy Volunteers

Myocardial Ischemia | Coronary Artery Disease (CAD)

China
Qingfeng Pharmaceutical Group

Unknown

Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia

Community Acquired Pneumonia

China
Livzon Pharmaceutical Group Inc.

Completed

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Stress Ulcer Bleeding

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine (Omicron)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Completed

LZM009 to Treat Patients With Advanced Solid Tumors

Solid Tumor

United States
Livzon Pharmaceutical Group Inc.

Unknown

Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH

Azoospermia | Oligospermia

China
Livzon Pharmaceutical Group Inc.

Unknown

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Gastroesophageal Reflux Disease
Livzon Pharmaceutical Group Inc.

Completed

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)

Duodenal Ulcer

China
Livzon Pharmaceutical Group Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of LZM012 (Psoriasis)

Psoriasis

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

COVID-19 Pandemic

Philippines, Indonesia, Russian Federation
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Completed

Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Peptic Ulcer Hemorrhage
Livzon Pharmaceutical Group Inc.

Completed

IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Peptic Ulcer Hemorrhage
Livzon Pharmaceutical Group Inc.

Completed

Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori

Helicobacter Pylori Eradication
Livzon Pharmaceutical Group Inc.

Completed

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Gastroesophageal Reflux Disease
Livzon Pharmaceutical Group Inc.

Completed

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (COVID-19)

COVID-19 Pandemic

Malaysia, Pakistan
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Unknown

Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .

Carcinogenic Fatigue

China
Livzon Pharmaceutical Group Inc.

Completed

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

Duodenal Ulcer
Livzon Pharmaceutical Group Inc.

Completed

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)

Duodenal Ulcer

China

3

Subscribe